Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 8, 2003, Pages 3663-3668

  Schutt, Florian ^a,b   Bergmann, Marion ^a   Holz, Frank G ^a   Kopitz, Jurgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Ophthalmology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT; LIPOFUSCIN; MALONALDEHYDE;

ARTICLE; CORNEA TRANSPLANTATION; EYE; HUMAN; IMMUNOHISTOCHEMISTRY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETINA; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALDEHYDES; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EYE PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID PEROXIDATION; LIPOFUSCIN; MALONDIALDEHYDE; OXIDATION-REDUCTION; PIGMENT EPITHELIUM OF EYE; PROTEOME;

EID: 0041342065     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0172     Document Type: Article

References (43)

1. Mata NL, Wenig J, Travis GH. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci USA. 2000;97:7154-7159.
2. Marmorstein AD, Marmorstein LY, Sakaguchi H, Hollyfield JG. Spectral profiling of autofluorescence associated with lipofuscin, Bruch's membrane, and sub-RPE deposits in normal and AMD eyes. Invest Ophthalmol Vis Sci. 2002;43:2435-2441.
3. Schraermeyer U, Heimann K. Current understanding on the role of retinal pigment epithelium and its pigmentation. Pigment Cell Res. 1999;12:219-236.
4. Shamsi FA, Boulton M. Inhibition of RPE lysosomal and antioxidant activity by the age pigment lipofuscin. Invest Ophthalmol Vis Sci. 2001;42:3041-3046.
5. Brunk U, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33:611-619.
6. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal epithelium: a review. Eye. 1995;9:763-771.
7. Schutt F, Ueberle B, Schnolzer M, Holz FG, Kopitz J. Proteome analysis of lipofuscin in human retinal pigment epithelial cells. FEBS Lett. 2002;528:217-221.
8. Berman ER, Rothman MS. Lipofuscin of human retinal pigment epithelium. J Ophthalmol. 1980;90:783-791.
9. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde, and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
10. Poli G, Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. Int Union Biochem Mol Biol Life. 2000;50:315-321.
11. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223-234.
12. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation end products (RAGE) and the complications of diabetes. Ageing Res Rev. 2002;1:1-15.
13. Shimokawa I, Higami Y, Horiuchi S, Iwasaki M, Ikeda T. Advanced glycation end products in adrenal lipofuscin. J Gerontol A Biol Sci Med Sci. 1998;53:B49-B51.
14. Kim HC, Bing G, Jhoo WK, et al. Oxidative damage causes formation of lipofuscin-like substances in the hippocampus of the senescence-accelerated mouse after kainate treatment. Behav Brain Res. 2002;131:211-220.
15. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA. 2002;99:14682-14687.
16. Holz FG, Bellmann C, Staudt S, Schutt F, Volcker HE. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001; 42:1051-1056.
17. Yin D. Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores. Free Radic Biol Med. 1996;21:871-888.
18. Boulton M, Docchio F, Dayhaw-Barker P, Ramponi R, Cubeddu R. Age-related changes in the morphology, absorption and fluorescence of melanosomes and lipofuscin granules of the retinal pigment epithelium. Vision Res. 1990;30:1291-1303.
19. Boulton M, Dayhaw-Barker P. The role of the retinal pigment epithelium: topographical variation and ageing changes. Eye. 2001;15:384-389.
20. Beatty S, Koh H, Phil M, Henson M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115-134.
21. Rozanowska M, Jarvis-Evans J, Korytowski W, Boulton ME, Burke JM, Sarna T. Blue light-induced reactivity of retinal age pigment: in vitro generation of oxygen-reactive species. J Biol Chem. 1995; 270:18825-18830.
22. Esterbauer H, Dieber-Rotheneder M, Waeg G, Striegel G, Jurgens G. Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol. 1990;3:77-92.
23. Montine T, Neely M, Quinn J, et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med. 2002;33:620-626.
24. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA. 1996;93:2696-2701.
25. Kumar RS, Anthrayose CV, Iyer KV, Vimala B, Shashidhar S. Lipid peroxidation and diabetic retinopathy. Indian J Med Sci. 2001;55:133-138.
26. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32.
27. Esterbauer H. Aldehydic products of lipid peroxidation. In: McBrien DCH, Slater TF: Free Radicals Lipid Peroxidation and Cancer. New York: Academic Press; 1982;101-128.
28. Montine TJ, Amarnath V, Martin ME, Strittmatter WJ, Graham DG. 4-Hydroxynonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol. 1996;148:89-93.
29. Sohal RS. Age Pigments. New York: Elsevier/North Holland Biomedical Press; 1981.
30. Tsai L, Szweda PA, Vinogradova O, Szweda LI. Structural characterisation and immunochemical detection of a fluorophore derived from 4-hydroxy-2-nonenal. Proc Natl Acad Sci USA. 1998;95:7975-7980.
31. Feeney-Burns L, Hilderbrand ES, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci. 1984;25:195-200.
32. Katz ML. Incomplete proteolysis may contribute to lipofuscin accumulation in the retinal pigment epithelium. Adv Exp Med Biol. 1989;266:109-116.
33. Burcham PC, Kuhan YT. Diminished susceptibility to proteolysis after protein modification by the lipid peroxidation product malondialdehyde: inhibitory role for crosslinked and non-crosslinked adducted proteins. Arch Biochem Biophys. 1997;340:331-337.
34. Holz FG, Schutt F, Kopitz J, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci. 1999;40:737-743.
35. Boulton M, Dontsov A, Jarvis-Evans J, Ostrovsky M, Svistunenko D. Lipofuscin is a photoinducible free radical generator. Photochem Photobiol B. 1993;19:201-204.
36. Ishibashi T, Murata T, Hangai M, et al. Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol. 1998;116:1629-1632.
37. Hammes HP, Hoerauf H, Alt A, et al. N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:1855-1859.
38. Schutt F, Davies S, Kopitz J, Holz FG, Boulton M. A2-E, a retinoid compound of lipofuscin, is photodamaging to human RPE cells. Invest Ophthalmol Vis Sci. 2000;41:2303-2308.
39. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
40. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retinal Eye Res. 2001;20:385-414.
41. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retinal Eye Res. 2001;20:705-732.
42. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Invest Drugs. 2001;10:1977-1987.
43. Stitt A, Gardiner TA, Anderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51:2826-2832.